Empiriko
Advancing Outcomes Through Innovation
banner_about_us.png

About

Empiriko Vision

about-us-banner.PNG
 
icon_liver.png

Empiriko has developed Biomimiks™ platform (in-vitro synthetic liver technology) to screen compounds for assessing drug metabolism and toxicity earlier in the drug discovery and development process.

 
 
icon_drop.png

Empiriko’s personalized diagnostics platform (Personalized Metabolic Fingerprint™ (PMF) device, biomarkers and predictive analytics) enables clinicians to manage at-risk patients at home more effectively. This real-time monitoring is critical for assessing the onset of disease, its progression and effectiveness of treatment - delivering the promise of personalized medicine at an affordable price.